International Assets Investment Management LLC Decreases Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

International Assets Investment Management LLC decreased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 85.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,969 shares of the company’s stock after selling 72,713 shares during the period. International Assets Investment Management LLC’s holdings in Recursion Pharmaceuticals were worth $86,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in RXRX. Commonwealth Equity Services LLC boosted its stake in Recursion Pharmaceuticals by 25.7% during the second quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company’s stock valued at $332,000 after buying an additional 9,058 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Recursion Pharmaceuticals by 24.1% during the 2nd quarter. Rhumbline Advisers now owns 281,348 shares of the company’s stock worth $2,110,000 after acquiring an additional 54,576 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after acquiring an additional 2,598 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Recursion Pharmaceuticals by 11.1% in the second quarter. Arizona State Retirement System now owns 47,691 shares of the company’s stock valued at $358,000 after purchasing an additional 4,760 shares in the last quarter. Finally, Plancorp LLC increased its position in Recursion Pharmaceuticals by 155.7% in the second quarter. Plancorp LLC now owns 70,610 shares of the company’s stock worth $530,000 after purchasing an additional 43,000 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Down 6.2 %

NASDAQ RXRX opened at $6.32 on Wednesday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $15.74. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of -4.13 and a beta of 0.85. The company has a fifty day moving average of $6.93 and a two-hundred day moving average of $6.97.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the prior year, the firm posted ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total transaction of $87,455.08. Following the completion of the transaction, the director now owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,894 shares of company stock worth $317,139 over the last 90 days. Company insiders own 15.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on RXRX shares. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $8.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.